This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days.
SemBiosys Genetics Inc. (SBS) SWOT Analysis report provides you a strategic analysis and detailed overview of the company’s businesses and operations.
In this report, our analysts reveal the company’s business strategy, strengths, weakness, opportunities and threats and detailed information such as :
- Key events associated with the company,
- Major products, services and brands of the company,
- Key competitors,
- Key executives, biographies and employment history,
- Personnel heading key departments and functions,
- Important locations and subsidiaries
- Financial analysis and ratios based on the annual financial statements published by the company including a 5 years history.
- Interim ratios for the last five interim periods
You get also in deepth information about SemBiosys Genetics Inc. (SBS) operations to identify potential customers, partners and suppliers. SemBiosys Genetics Inc. (SBS) business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Genomics Industry in Canada
Data table of Contents
Data table of Contents 2
List of Tables 4
List of Figures 4
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Deals By Year, from 2005 to 2011 5
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare Deals By Type, from 2005 to 2011 6
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal By Region, from 2005 to 2011 7
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, from 2005 to 2011 8
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal Summary, from 2005 to 2011 9
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal Details 10
Asset Purchase 10
SemBioSys Genetics Takes Over Platform-Enhancing Technology From Syngenta 10
Venture Financing 11
Botaneco Specialty Secures US$ 4 Mln In Financing 11
Private Equity 12
Avrio Ventures Completes The Acquisition Of Botaneco Specialty Ingredients 12
Equity Offering 13
SemBioSys Genetics Announces Private Placement 13
SemBioSys Completes Private Placement Of US$ 1.73 Mln 14
SemBioSys Genetics Completes Initial Closing Of Public Offering Of Units For US$ 4.15 Mln 16
SemBioSys Genetics Completes Private Placement Of US$ 10 Mln 18
SemBioSys Genetics Completes Public Offering Of US$ 13.5 Mln 20
SemBioSys Genetics Completes Private Placement Of US$ 15.5 Mln 22
Divestiture - Firms 23
Advitech Takes Over Botaneco Specialty From Avrio Ventures And SemBioSys 23
Acquisition 25
Advitech Takes Over Botaneco Specialty From Avrio Ventures And SemBioSys 25
Key Competitors 27
Key Employees 27
Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
November 07, 2008: Sembiosys Announces Third Quarter 2008 Financial And Operational Results 29
August 05, 2008: Sembiosys Announces Second Quarter 2008 Financial And Operational Results 30
May 09, 2008: Sembiosys Announces First Quarter 2008 Financial And Operational Results 32
March 17, 2008: Sembiosys Announces 2007 Financial And Operational Results 34
November 01, 2007: Sembiosys Announces 2007 Third Quarter Results 36
August 02, 2007: Sembiosys Announces 2007 Second Quarter Results 38
May 03, 2007: Sembiosys Announces First Quarter Results 39
March 15, 2007: Sembiosys Announces 2006 Results 41
November 06, 2006: Sembiosys Announces Third Quarter Results 43
May 03, 2006: Sembiosys Announces First Quarter Operational And Financial Results 44
March 15, 2006: Sembiosys Announces 2005 Year-End Operational And Financial Results 45
November 01, 2005: Sembiosys Announces Third Quarter Results 47
July 28, 2005: Sembiosys Announces Second Quarter Results 48
May 02, 2005: Sembiosys Announces First Quarter Results 49
March 15, 2005: Sembiosys Announces 2004 Year-End Operational And Financial Results 49
Corporate Communications 50
July 21, 2010: SemBioSys Appoints Rick Pierce As President of US and International Operations 50
May 07, 2009: SemBioSys Announces Board Changes 51
January 12, 2009: SemBioSys Announces Senior Management Changes 51
Product News 52
December 03, 2008: Sembiosys Begins Phase I/Ii Trial Of Insulin Produced In Plant Seeds 52
November 28, 2000: Sembiosys Genetics Inc. Receives Broad Us Patent For Its Oilbody Platform Technology 52
November 22, 2006: Sembiosys Signs Contract Manufacturing Agreement For Plant-Produced Insulin With Cangene 53
November 10, 2004: Sembiosys Receives U.S. Patent For Vaccine Production 53
November 03, 2006: Sembiosys Announces Successful Outcome Of Personal Care Product Appeal Proceedings At The European Patent Office 53
October 29, 2001: Sembiosys Genetics Inc. Receives Us Patent For Its Plant-Based Somatotropin Production Technology 54
September 16, 2008: Sembiosys Eligible To Proceed With Phase I/Ii Plant-Produced Insulin Trial After Submission Of Ind 54
September 07, 2006: Sembiosys Issued 20th U.S. Patent 55
September 01, 2010: Sembiosys Receives US Patent For Production Of Apolipoproteins In Plants 55
August 11, 2009: Sembiosys Completes Pre-Ind Meeting With U.S. Fda For Apo Ai(Milano) 56
July 30, 2009: Sembiosys Awarded Key U.S. Patent For The Production Of Insulin In Plants 56
July 30, 2009: SemBioSys Receives US Patent For Production Of Insulin In Plants 56
July 29, 2008: Sembiosys Submits Ind For Safflower-Produced Insulin To U.S. Fda 57
July 29, 2003: Sembiosys Genetics Receives Eleventh And Twelfth U.S. Patents For Oilbody-Based Technology 57
June 26, 2007: Sembiosys Presents Positive Insulin Data At The American Diabetes Association Conference 58
June 05, 2009: Data For Sembiosys Insulin To Be Presented At The American Diabetes Associations 69th Scientific Sessions 58
May 26, 2005: Sembiosys Receives License Payment From Lonza 59
May 19, 2009: Sembiosys Plant-Derived Apo Ai(Milano) Demonstrates Encouraging Biologic Activity In Seven Preclinical Models 59
May 13, 2002: Sembiosys Genetics Receives Ninth U.S. Patent For Oil Body-Based Technology 60
April 14, 2008: Botaneco Announces Launch Of Second Generation Oleosome Product 60
March 26, 2008: Sembiosys Initiates Toxicology Study For Safflower-Produced Insulin 61
March 19, 2009: Sembiosys Genetics Inc. Announces Clinical Results With Plant-Produced Insulin 61
March 13, 2008: Sembiosys Awarded Key Patent For The Production Of Oleosome Emulsions By The European Patent Office 62
February 04, 2003: Sembiosys Genetics Receives Tenth U.S. Patent For Oil Body-Based Technology 63
February 01, 2010: Sembiosys Plant-Made Biosimilar Insulin Featured On Ctv News, Canada Am 63
January 27, 2006: Fda Approves Exubera, Pfizers Inhaled Insulin 64
January 18, 2010: Sembiosys Provides Update On Gla-Rich Safflower Oil 65
January 03, 2007: Sembiosys To Proceed With Abbreviated Regulatory Path For Plant- Produced Insulin After Meeting With The Fda 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67
List of Tables
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Major development, 2009 1
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Deals By Year, from 2005 to 2011 1
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal By Region, from 2005 to 2011 1
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, from 2005 to 2011 1
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal Summary, from 2005 to 2011 1
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Deals By Year, from 2005 to 2011 5
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare Deals By Type, from 2005 to 2011 6
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal By Region, from 2005 to 2011 7
SemBiosys Genetics Inc., Deals By Therapy Area, from 2005 to 2011 8
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal Summary, from 2005 to 2011 9
SemBioSys Genetics Takes Over Platform-Enhancing Technology From Syngenta 10
Botaneco Specialty Secures US$ 4 Mln In Financing 11
Avrio Ventures Completes The Acquisition Of Botaneco Specialty Ingredients 12
SemBioSys Genetics Announces Private Placement 13
SemBioSys Completes Private Placement Of US$ 1.73 Mln 14
SemBioSys Genetics Completes Initial Closing Of Public Offering Of Units For US$ 4.15 Mln 16
SemBioSys Genetics Completes Private Placement Of US$ 10 Mln 18
SemBioSys Genetics Completes Public Offering Of US$ 13.5 Mln 20
SemBioSys Genetics Completes Private Placement Of US$ 15.5 Mln 22
Advitech Takes Over Botaneco Specialty From Avrio Ventures And SemBioSys 23
Advitech Takes Over Botaneco Specialty From Avrio Ventures And SemBioSys 25
SemBiosys Genetics Inc., Key Executives 27
SemBiosys Genetics Inc., Subsidiaries 28
List of Figures
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Deals by Type, from 2005 to 2011 1
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Deals By Year, from 2005 to 2011 5
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Deals by Type, from 2005 to 2011 6
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal By Region, from 2005 to 2011 7
SemBiosys Genetics Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, from 2005 to 2011 8
Companies mentioned
Nuvo Research Inc.
XPhase Pharmaceuticals, Inc.
BioAxone Therapeutic Inc.
Epitome Pharmaceuticals Ltd.
Seaford Pharmaceuticals Inc.
